so it is really only one board in essence. One thing that I overlooked and perhaps is the reason why the nice little upward momentum is that this smallcap pharma has been given an oral presentation. This does not happen often. That is pretty good. Doubt they would have been given an oral based on the November data. So something looks to be improved in a short span. I still say, It all depends on DOR and PFS. If we can get anything over 9 on DOR with a tail, and over 13 on the PFS, we are partner bound. If C797S has any positive new info, where it is worth a meeting with the FDA, i think we are golden and will see a surge over the next 15 months. Buyers want more than just one treatment, BDTX will hopefully give them 3, with potential to take market share from competitors. That is why I am holding.
Market Data 
Markets 
AI
